文献速递心脑血管急症呼吸衰竭与机械通气重症综合管理与镇静镇痛

系统性硬化症相关肺动脉高压的长期结局:来自PHAROS注册研究

Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
PubMed 文献 · Chest · 2018-05-16
一句话结论PHAROS注册研究中160例新发系统性硬化症相关肺动脉高压患者1、3、5、8年生存率分别为95%、75%、63%、49%,肺动脉高压占全部死亡的52%。

该研究为PHAROS前瞻性注册研究,纳入经右心导管确诊的新发世界卫生组织第1组肺动脉高压的系统性硬化症患者160例,评估长期结局。患者1、3、5、8年生存率分别为95%、75%、63%、49%;肺动脉高压占全部死亡的52%,其中93%的肺动脉高压相关死亡发生在诊断后4年内。多因素Cox回归显示男性、弥漫性疾病、心电图估测收缩期肺动脉压、右心导管平均肺动脉压、6分钟步行距离和弥散功能一氧化碳是生存的显著影响因素。作者认为优化早期肺动脉高压相关死亡高风险患者的治疗至关重要。

要点

  • 160例新发系统性硬化症相关肺动脉高压患者1、3、5、8年生存率分别为95%、75%、63%、49%。
  • 肺动脉高压占全部死亡的52%,93%的肺动脉高压相关死亡发生在诊断后4年内。
  • 多因素分析中男性(HR 3.11;95%CI 1.38-6.98)和弥漫性疾病(HR 2.12;95%CI 1.13-3.93)与生存显著相关。
  • 右心导管平均肺动脉压(HR 1.03;95%CI 1.001-1.07)和心电图估测收缩期肺动脉压(HR 1.06;95%CI 1.01-1.11)与生存显著相关。
  • 6分钟步行距离(HR 0.92;95%CI 0.86-0.99)和弥散功能一氧化碳(HR 0.65;95%CI 0.46-0.92)与生存显著相关。

适用人群与场景

  • PHAROS前瞻性注册研究中经右心导管确诊为新发世界卫生组织第1组肺动脉高压的系统性硬化症患者160例。

研究设计与关键结果

  • 研究类型为前瞻性注册研究,纳入160例新发系统性硬化症相关肺动脉高压患者,生存率1年95%、3年75%、5年63%、8年49%。
  • 肺动脉高压占全部死亡的52%;仅分析肺动脉高压相关死亡时,1、3、5、8年生存率分别为97%、83%、76%、76%,93%的肺动脉高压相关死亡发生在诊断后4年内。
  • 多因素Cox回归显示男性(HR 3.11;95%CI 1.38-6.98)、弥漫性疾病(HR 2.12;95%CI 1.13-3.93)、心电图估测收缩期肺动脉压(HR 1.06;95%CI 1.01-1.11)、右心导管平均肺动脉压(HR 1.03;95%CI 1.001-1.07)、6分钟步行距离(HR 0.92;95%CI 0.86-0.99)和弥散功能一氧化碳(HR 0.65;95%CI 0.46-0.92)显著影响生存。

证据类型、等级与局限

  • 证据类型为前瞻性注册研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,优化早期肺动脉高压相关死亡高风险患者的治疗至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH.

METHODS: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma is a prospective registry of patients with SSc at high risk for or with incident pulmonary hypertension from right heart catheterization. Incident World Health Organization group I PAH patients were analyzed. Kaplan-Meier survival curves were generated for the overall cohort and those who died of PAH. Multivariate Cox regression models identified predictors of mortality.

RESULTS: Survival in 160 patients with incident SSc-PAH at 1, 3, 5, and 8 years was 95%, 75%, 63%, and 49%, respectively. PAH accounted for 52% of all deaths. When restricted to deaths from PAH, respective survival rates were 97%, 83%, 76%, and 76%, with 93% of PAH-related deaths occurring within 4 years of diagnosis. Men (hazard ratio [HR], 3.11; 95% CI, 1.38-6.98), diffuse disease (HR, 2.12; 95% CI, 1.13-3.93), systolic pulmonary artery pressure (PAP) on ECG (HR, 1.06 95% CI, 1.01-1.11), mean PAP on right heart catheterization (HR, 1.03; 95% CI, 1.001-1.07), 6-min walk distance (HR, 0.92; 95% CI, 0.86-0.99), and diffusing capacity for carbon monoxide (HR, 0.65; 95% CI, 0.46-0.92) significantly affected survival on multivariate analysis.

CONCLUSIONS: Overall survival in PHAROS was higher than other SSc-PAH cohorts. PAH accounted for more than one-half of deaths and primarily within the first few years after PAH diagnosis. Optimization of treatment for those at greatest risk of early PAH-related death is crucial.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Kolstad KD, Li S, Steen V, et al. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest. 2018. PMID: 29777655. doi:10.1016/j.chest.2018.05.002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。